profit from every $100 of sales.
$0$100
Masimo
We have no price for Masimo since 12 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$179.95+0.00% today
+21.6% since Oct 13, 25
1-year low $127.401-year high $179.95
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Masimo sold, what it kept, and what it did with the cash.
Sales went from $2.04 billion in 2022 to $1.53 billion in 2025, with -$152 million of profit last year.
SalesProfit
Masimo handed back more cash to shareholders than it generated last year.
Buybacks $364M
Free cash flow 2025$193M
Bought back its own shares$364M
Paid as dividends–
Cash vs. debt$152M vs. $559M
Masimo vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Masimo | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Masimo's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,036 | 1,276 | 1,395 | 1,527 | |
| 1,059 | 766 | 794 | 945 | |
| 210 | 184 | 64 | 313 | |
| 355 | 199 | 112 | 345 | |
| 144 | 82 | -305 | -152 | |
| 2.60 | 1.51 | -5.72 | -2.83 | |
| 52.0% | 60.0% | 56.9% | 61.9% | |
| 10.3% | 14.4% | 4.6% | 20.5% | |
| 7.0% | 6.4% | -21.9% | -9.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,211 | 3,042 | 2,626 | 1,699 |
| Cash | 203 | 163 | 124 | 152 |
| Total debt | 1,029 | 970 | 762 | 559 |
| Total liabilities | 1,872 | 1,677 | 1,574 | 978 |
| 1,339 | 1,365 | 1,052 | 721 | |
| 55 | 54 | 53 | 54 | |
| 7.3% | 5.4% | 2.7% | 18.9% | |
| 10.7% | 6.0% | -29.0% | -21.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 29 | 94 | 196 | 218 | |
| 56 | 62 | 38 | 25 | |
| -27 | 32 | 158 | 193 | |
| Dividends paid | – | – | – | – |
| 402 | 0 | 0 | 364 | |
| 48 | 6 | 36 | 36 |
Valuation
- –
- 30.4×
- –
- 11.8×
- 6.2×
- 48.8×
- 28.5×
- 2.0%
- -1.6%
- 0.0%
Profitability
- 61.9%
- 20.5%
- -9.9%
- 22.1%
- 18.3%
- -0.8%
- 9.1%
- 4.6%
- 23.5%
- 7.9%
Growth
- −9.1%
- –
- +36.1%
- –
- −0.7%
Financial health
- 1.0×
- 0.62
- 29.6%
- 10.1×
- 2.68
- 1.45
- 0.95
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 964
Top 25%of 898
Bottom 8%of 911
Top 46%of 991
What analysts expect
- Average price target
- $187.50
- Range
- $180.00 – $200.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 1.10 | 1.41 | −22.0% |
| Feb 26, 2026 | 0.18 | 1.48 | −87.8% |
| Nov 4, 2025 | 1.32 | 1.19 | +10.9% |
| Aug 5, 2025 | 1.33 | 1.23 | +8.1% |
| May 6, 2025 | 1.36 | 1.24 | +9.7% |
| Feb 25, 2025 | 1.80 | 1.42 | +26.8% |
| Nov 5, 2024 | 0.98 | 0.84 | +17.1% |
| Aug 6, 2024 | 0.86 | 0.77 | +11.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
35No pass
Philip Fisher
47No pass
Peter Lynch
25No pass
Joel Greenblatt
14No pass
Charlie Munger
43No pass
Terry Smith
33No pass
Questions about Masimo
Is Masimo a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Masimo AI analysis
What does Masimo do?
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. It is in Medical - Devices, based in Irvine, CA, United States, with 2,200 employees.
Does Masimo pay a dividend?
No. Masimo does not pay a dividend at the moment; in 2025 it returned $364 million to shareholders by buying back its own shares.
Is Masimo stock halal?
Yes. Masimo passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
Who are Masimo's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Masimo's.
Prices: daily closes to Jun 12, 2026. Fundamentals: company reports via invest-like data.